Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Regulation Approvals

Keeping Track: Nucala, Genvoya Approved; New Breakthrough Claims For Daiichi Sankyo, Merck Oncologics

  • Analysis

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

You may also be interested in...



Keeping Track Of Oncology: US FDA Approves Herceptin Hylecta, Reviews Darolutamide And Pexidartinib

Oncology news and highlights from our US FDA Performance Tracker.

Keeping Track: Immuno-Oncologics And Abuse-Deterrent Opioids Take Center Stage (Again); Jardiance CV Claim Approved

The latest drug development news and highlights from our FDA Performance Tracker.

Keeping Track: Rebyota, Rezlidhia Rev Up US FDA Approvals; New Sponsors Sought For Poziotinib, Brexafemme

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Table

View full table

Topics

Related Companies

Tags:
BioPharmaceutical Regulation Approvals
Latest News

To Prevent Shortages, US FDA Wants Sponsor To Provide Notifications Of Demand Spike

Eisai Plots A Meticulous Path To Medicare Coverage For Lecanemab

US FDA’s Non-Cancer Accelerated Approval Drugs Get Their Own Public Databases

Recent And Upcoming FDA Advisory Committee Meetings

See All
UsernamePublicRestriction

Register

PS057250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By